•   
  •   

World India’s health workers baulk at taking homegrown COVID vaccine

14:41  25 february  2021
14:41  25 february  2021 Source:   aljazeera.com

Experts feared India's farming protests would be COVID superspreader events. Poverty, misinformation and a younger population may explain why cases plummeted instead.

  Experts feared India's farming protests would be COVID superspreader events. Poverty, misinformation and a younger population may explain why cases plummeted instead. Mass gatherings such as the farmers' protests didn't become the superspreader events experts feared. COVID cases have steadily fallen, raising hopes the country is close to achieving herd immunity. One expert says misinformation may have been an "accidental game changer" at encouraging mingling. Visit the Business section of Insider for more stories. When Indian farmers began gathering to protest in November 2020, at the height of the coronavirus pandemic, experts predicted these would be superspreader events.

India is struggling to convince its healthcare and front-line workers to take a homegrown COVID-19 vaccine controversially approved without late-stage efficacy data, government data showed on Thursday, days ahead of a wider roll-out.

a hand holding a bottle: India's Health Minister Harsh Vardhan holds a dose of Bharat Biotech's COVAXIN [File: Adnan Abidi/Reuters] © India's Health Minister Harsh Vardhan holds a dose of Bharat Biotech's COVAXIN [File: Adnan Abidi/Re... India's Health Minister Harsh Vardhan holds a dose of Bharat Biotech's COVAXIN [File: Adnan Abidi/Reuters]

The country has the world’s second-highest number of COVID-19 infections after the United States, with cases recently surging as mask-wearing declines and states have eased social distancing measures.

How a Black bioethicist makes the case for vaccination to people of color

  How a Black bioethicist makes the case for vaccination to people of color “I think it’s a moral obligation,” says Keisha Ray.This has been a long-running debate among ethicists since well before the coronavirus pandemic. Some philosophers argue that everyone has a moral obligation to be vaccinated against infectious diseases like measles, while others say it’s not so simple. It’s a debate that gets at fundamental questions about individual liberty, bodily autonomy, and communal obligation.

A lack of confidence in a homegrown vaccine could prevent India from meeting its target of vaccinating 300 million of its 1.35 billion people by August.

India has vaccinated more than 10.5 million healthcare and front-line workers since beginning its immunisation campaign on January 16.

But only 1.2 million, or about 11 percent, of them, have taken COVAXIN, the locally developed vaccine from Bharat Biotech, while the remaining 9.4 million have used the vaccine licensed from AstraZeneca, according to the government’s Co-Win online platform used to track the vaccination drive.

India’s federal government has so far ordered 10 million doses of COVAXIN and 21 million doses of the Oxford-AstraZeneca shot. The government says it has received at least 5.5 million COVAXIN doses.

Delivery of Over A Million COVID Vaccines Shots Delayed by U.S. Winter Storm

  Delivery of Over A Million COVID Vaccines Shots Delayed by U.S. Winter Storm Vaccine shipment delays were reported in several southern and Midwestern states, including Texas, Florida, Georgia and Michigan.The delivery of over a million COVID-19 vaccine doses have been impacted so far, including 407,000 first doses and 333,650 second doses in Texas, 200,000 total doses in Florida and 133,000 in Colorado.

“It’s all because of the initial discussion about how [COVAXIN] was only an experimental vaccine, how it had not completed the Phase-3 trial,” said Dr Subhash Salunkhe, who advises the Maharashtra state government on vaccine strategy.

“These things created doubts in the minds of people, resulting in lesser acceptance. The availability is not a concern at this juncture.”

However, India’s health secretary Rajesh Bhushan on Tuesday attributed the lower uptake of COVAXIN to Bharat Biotech’s limited production capacity compared with that of the Serum Institute of India, the world’s biggest vaccine producer, which is making the AstraZeneca shot for low- and medium-income countries.

“We have found that in proportion to the quantity of vaccine available with us, [COVAXIN’s] off-take is fairly satisfactory,” told a news conference.

The health ministry did not respond to a request for comment on the latest figures showing that only about 12 percent of the ordered doses had been administered.

Australia's COVID-19 vaccine rollout now has some certainty but there are still many unknowns

  Australia's COVID-19 vaccine rollout now has some certainty but there are still many unknowns The announcements about Australia's COVID-19 vaccine rollout have been travelling at warp speed this week and although there are now some guarantees, there are still many unknowns."The eagle has landed," Health Minister Greg Hunt announced on Monday, declaring 142,000 doses of the Pfizer vaccine had touched down in Australia — after much nervousness.

Earlier this month, Chhattisgarh, an opposition-governed state of 32 million people, told the federal government it would not use COVAXIN until its efficacy could be proven in an ongoing late-stage trial.

Epidemiologist and public health experts have also criticised the COVAXIN approval as rushed.

Bharat Biotech has said efficacy data from the trial on nearly 26,000 volunteers will be out soon. The company, along with India’s drug regulator, says the vaccine is safe and effective based on early and intermediate studies.

Bharat Biotech did not immediately comment on the lower uptake of its vaccine.

The government is trying to expedite vaccinations as cases have surged, especially in Maharashtra in the west and the southern state of Kerala, possibly as they have reopened suburban trains and schools.

Mask-wearing and social distancing have also largely vanished, with big events like international cricket matches being played in front of tens of thousands of spectators hardly following any COVID-19 rules.

India reported 16,738 new coronavirus infections in the past 24 hours, the highest daily jump in a month, health ministry data showed on Thursday, raising the total to 11.05 million.

More than half of the new cases were in Maharashtra, India’s richest and home to its financial capital Mumbai, which reported a record high of 8,807 cases on Wednesday.

Deaths across the country rose by 138, also the highest in a month, taking the total to 156,705.

The key ingredient that could hold back vaccine manufacturing .
You may not have heard of them, but lipid nanoparticles are key to the Moderna and Pfizer vaccines.Here’s part of the answer: We’re still racing to make a special type of lipid, a relatively unknown but critical component of the vaccines being manufactured by Moderna and Pfizer/BioNTech. These vaccines use messenger RNA, the genetic component commonly known as mRNA that instructs cells to make proteins, which in turn teach the human body how to fight the virus that causes Covid-10.

usr: 0
This is interesting!